Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Andrew Miller

Karuna Therapeutics, Inc.

At Karuna, our purpose is to create and deliver transformative medicines for people living with psychiatric and neurological conditions. 
 
Through the cultivation of our deep expertise in neuroscience, and inventive thinking around drug discovery and development, we are advancing a pipeline of novel medicines with the goal of providing a meaningful difference in the lives of those affected by these conditions.
 
Our culture is defined by our passion to serve those affected by mental illness. We are purpose-driven and intentional. We know impactful innovations don’t come easy, but are borne from passion and hard work. Together, we are working toward a goal bigger than ourselves.
 
We invite you to join us on LinkedIn and Twitter (@KarunaTx) to stay up to date on our work.

Eventide

Fidelity

Fidelity Management and Research Company

Alexandria Venture Investments

Sands Capital Ventures

Sofinnova Investments

ARCH Venture Partners

Partner Fund Management

Pivotal bioVenture Partners

PureTech Health

Wellcome Trust

Karuna Therapeutics

Today on #February11, we join others around the globe to celebrate International Day of Women and Girls in Science. We especially want to recognize the brilliant women in science on our team. Their leadership and dedication are helping us push the boundaries of innovation in neuroscience, and the best is yet to come! #EquityinScience

Bebe Moore Campbell was a fearless mental health advocate and literary trailblazer who used her words and platform to address the impacts of racism, mental health, culture, and community. This #BlackHistoryMonth, we honor and remember her legacy as well as other Black pioneers who helped shape the #MentalHealth landscape. Learn more about their contributions: https://lnkd.in/dPDdCfR

Schizophrenia is a brain disorder that distorts the way a person thinks, feels, and behaves. While current antipsychotic therapies can help treat some symptoms, such as hallucinations and delusions, they may not fully address symptoms such as memory impairment, decision-making, and the ability to enjoy life – leading to low treatment adherence. Learn more about our commitment to addressing these needs: https://lnkd.in/gmN8ykmx 

Signs and symptoms of #schizophrenia are not “one size fits all.” Schizophrenia symptoms can differ from person to person, but they generally fall into three categories. Learn more about them here: https://lnkd.in/gmN8ykmx 

Wishing you #HappyHolidays from all of us at Karuna! May you find peace and enjoy the company of your loved ones during this season. 

Metric
Company Name	Karuna Therapeutics, Inc.
Symbol	KRTX
MSH ID	COM:KARUNATX
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	339
Website	karunatx.com
LinkedIn	karuna-therapeutics
Founders

Metric
Market Cap	12.60B
Enterprise Value
Monthly Web Traffic	29.34K
Web Traffic Growth	0.07
Valuation
Raised Capital

Metric
Revenue	654K
Revenue (LTM)
Revenue (NTM)
Gross Profit	-1.05M
EBITDA	-493.08M
Operating Income	-494.78M
Net Income	-433.68M
EPS	-11.73
Diluted EPS	-11.73
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-1.60
Operating Profit Margin	-756.54
EBITDA Margin	-753.94
Net Profit Margin	-645.55
Return on Equity	-0.31
Return on Assets	-0.32
Return on Capital Employed	-0.39

COM:KARUNATX

Karuna Therapeutics, Inc.

Last Close

329.74

15/03 20:00

Market Cap

12.60B

Beta: -

Volume Today

1.28M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-31.06
P/B Ratio	9.03
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	19.26K
EV Multiple	-25.83

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding	7.04K
Operating Cycle	9.78K
Cash Conversion Cycle	8.32K
Asset Turnover	0.00

Metric
Operating Cash Flow	-385.82M
Free Cash Flow	-388.74M
Cash Flow to Debt	-23.12
Operating Cash Flow/Sales	-589.94
Free Cash Flow Yield	-0.02

Metric
Cash & Equivalents	185.82M
Accounts Receivable	57K
Inventory	32.83M
Goodwill
Debt to Capitalization	0.01
Debt to Assets	0.01
Current Ratio	27.88
Quick Ratio	18.61

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	7.78
R&D to Revenue	58.65
SG&A to Revenue	18.25